title: Association between the Thr241Met polymorphism of X-ray repair cross-complementing group 3 gene and glioma risk: evidence from a meta-analysis based on 4,136 cases and 5,233 controls.
abstract: Genetic polymorphism of X-ray repair cross-complementing group 3 (XRCC3) Thr241Met has been implicated to alter the risk of glioma, but the results are controversial. Medline, PubMed, Embase, and Cochrane Library databases were independently searched by two investigators up to 13 July 2013. Summary odds ratios (OR) and 95% confidence interval (CI) for Thr241Met polymorphism and prostate cancer were calculated. Statistical analysis was performed with the software program Stata 12.0. A total of 10 independent studies, including 4,136 cases and 5,233 controls, were identified. Our analysis suggested that Thr241Met was not associated with glioma risk in overall population. In the subgroup analysis, we detected no significant association between Thr241Met polymorphism and glioma risk in different descent populations. Subgroup analysis was held by source of controls, significant association was found between this polymorphism and glioma risk for population-based studies (homozygote model: OR = 1.747, 95% CI = 1.123-2.717, Ph = 0.059, I(2) = 59.7%; recessive model, OR = 1.455, 95% CI = 1.179-1.795, Ph = 0.111, I(2) = 50.1%; allele model, OR = 1.258, 95% CI = 1.010-1.566, Ph = 0.011, I(2) = 72.9%). This meta-analysis showed the evidence that XRCC3 Thr241Met polymorphism was associated with a low risk of glioma development.
authors.affiliation: Department of Neurosurgery, General Hospital of Shenyang Military Region, 83 Wenhua Road, Shenyang, 110840, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Lin
authors.forename: Yun
authors.initials: Y
authors.lastname: Kou
mesh_terms: D000483:Alleles; D001932:Brain Neoplasms / Q000235:genetics*; D016022:Case-Control Studies; D004268:DNA-Binding Proteins / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D005838:Genotype; D005910:Glioma / Q000235:genetics*; D006801:Humans; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D017594:Publication Bias; D012306:Risk
chemical_list: D004268:DNA-Binding Proteins; C110901:X-ray repair cross complementing protein 3
references.citation: Cancer Res. 1992 Oct 15;52(20):5590-6
references.pmid: 1394182
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Lancet. 1997 Oct 18;350(9085):1182
references.pmid: 9343537
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: J Natl Cancer Inst. 2001 Oct 17;93(20):1553-7
references.pmid: 11604478
references.citation: Cancer Causes Control. 2003 Mar;14(2):139-50
references.pmid: 12749719
references.citation: Neuro Oncol. 2010 Jan;12(1):37-48
references.pmid: 20150366
references.citation: Int J Epidemiol. 2008 Feb;37(1):120-32
references.pmid: 17898028
references.citation: Cancer Epidemiol. 2010 Feb;34(1):55-61
references.pmid: 20061201
references.citation: Int J Mol Sci. 2013 Feb 05;14(2):3314-24
references.pmid: 23385236
references.citation: Mutat Res. 2002 Nov 30;509(1-2):49-78
references.pmid: 12427531
references.citation: J Biol Chem. 1998 Aug 21;273(34):21482-8
references.pmid: 9705276
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Cancer Causes Control. 1994 Mar;5(2):177-87
references.pmid: 8167265
references.citation: Mutat Res. 2005 Feb 15;570(1):105-17
references.pmid: 15680408
references.citation: Asian Pac J Cancer Prev. 2013;14(1):449-52
references.pmid: 23534771
references.citation: Biometrics. 1994 Dec;50(4):1088-101
references.pmid: 7786990
references.citation: Nat Genet. 2001 Mar;27(3):247-54
references.pmid: 11242102
references.citation: Int J Cancer. 2009 Jun 15;124(12):2948-53
references.pmid: 19330829
references.citation: J Neurooncol. 2008 Jun;88(2):135-42
references.pmid: 18330515
references.citation: Cancer Causes Control. 2002 Sep;13(7):647-55
references.pmid: 12296512
references.citation: BMC Cancer. 2013 May 10;13:234
references.pmid: 23663450
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Diabetologia. 1998 Jan;41(1):47-53
references.pmid: 9498629
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):204-14
references.pmid: 19124499
references.citation: Mutat Res. 2004 Nov 22;556(1-2):169-81
references.pmid: 15491645
references.citation: Cancer Res. 2004 Aug 15;64(16):5560-3
references.pmid: 15313891
references.citation: Int J Cancer. 2011 Feb 15;128(4):944-50
references.pmid: 20473903
references.citation: Int J Biol Markers. 2009 Apr-Jun;24(2):77-82
references.pmid: 19634110
references.citation: Trans Am Neurol Assoc. 1976;101:273-5
references.pmid: 1028258
references.citation: Asian Pac J Cancer Prev. 2012;13(10):4905-8
references.pmid: 23244079
references.citation: Genet Mol Res. 2012 Feb 10;11(1):332-9
references.pmid: 22370935
references.citation: Acta Neuropathol. 2005 Jan;109(1):93-108
references.pmid: 15685439